Implied Podcast

Dave Inc. (DAVE) just capped off a brutal week, plunging nearly 23% amid Fed controversy and fears of new banking regulations. The twist? The company just refinanced its debt and analysts argue it has zero exposure to the fees driving the market panic. In this episode, we break down the massive disconnect between Dave’s crashing stock price and its booming 63% revenue growth. Is this a "mistaken i...

Figma, the design powerhouse that nearly merged with Adobe for $20 billion, is now trading around $36 —a staggering 75% drop from its $142 post-IPO high . But don't let the price tag fool you. While the stock looks like a "broken IPO," the business is hitting massive milestones, including crossing the $1 billion annual revenue run rate with 38% growth . In this episode of Implied , we peel back th...

Abercrombie & Fitch just saw an 18% hole blown in its stock chart, despite reporting record holiday demand. Why the panic? Wall Street is fixating on a new $90 million tariff bill and rising capital expenses, ignoring the brand’s massive turnaround success. In this episode, we break down why "good" isn't good enough for this market anymore and analyze the setup: is this a warning signal for re...

Coty shares are seeing ghosts, trading near 52-week lows at $3.06 after being practically cut in half over the last year. Despite a massive $750 million cash injection from selling its Wella stake, Wall Street is terrified by a sudden CEO shakeup and a wider crisis hitting rival Estée Lauder. In this episode, we break down why the market hates the uncertainty—and why they might be missing the mass...

American International Group just surrendered months of gains, shedding nearly 10% in a bloodbath week after a surprise "reserve strengthening" announcement. Investors are fleeing as fears mount that the insurer’s underwriting models are fundamentally broken and "structural damage" has been done. In this episode of Implied, we break down the critical "Combined Ratio" miss, why the market is having...

Regencell Bioscience (RGC) just went from a massive 60% rally to a sudden 20% plunge in less than 24 hours—and there is absolutely zero news to explain it. Despite having a market cap floating around $10 billion, the company has generated effectively no revenue and is trading at a staggering 5,000x book value. In this episode, we break down the dangerous mechanics behind this "roller coaster," the...

SiTime just erased $1 billion in market value in a single session, falling over 10% despite being the heartbeat of modern AI infrastructure. The stock has been a rocket ship—up 56% in the last year—but today it sliced through key technical levels as investors finally questioned its astronomical valuation. Is this a disastrous breakdown, or a rare chance to buy the "Endura" defense play at a discou...

Just 24 hours ago, D-Wave Quantum was flying high on CES 2026 news—but today, the stock crashed nearly 10%. Why? A top executive just unloaded $24 million worth of shares right into the rally. In this episode of Implied, we break down whether this massive insider sale signals a lack of confidence or just a smart cash-out. With an $11 billion valuation on just $3.74 million in quarterly revenue, is...

Axia Energia (formerly Eletrobras) is getting hammered, shedding nearly 10% as its massive rebrand hits a wall. The trigger? A controversial new deal for a green hydrogen plant that investors see as pure cash burn rather than innovation. In this episode, we break down why the market is aggressively rejecting Axia’s pivot from boring utility dividends to high-stakes tech, and whether this selloff i...

Nike just face-planted with a massive 10% drop, despite technically beating earnings estimates. Why the bloodbath? The "turnaround" just hit a reality check: crushing tariffs have destroyed margins, and sales in China are in freefall. In this episode of Implied, we look past the headline numbers to explain why CEO Elliott Hill’s "middle innings" narrative isn't sticking. Is the sales jump in North...

Insmed’s 200% rally just hit a brutal wall. The stock crashed 17% after its star drug, Brinsupri, failed a key Phase 2 study—shattering the thesis that it could be a "Swiss Army Knife" for inflammation. Even a surprise acquisition announcement couldn't distract Wall Street from the flop. In this episode, we break down the failed "misdirection" play and analyze the wreckage: Is this a disastrous si...

GE Vernova just baffled Wall Street with a massive 10% crash on the exact same day it received a "Strong Buy" upgrade from Evercore ISI. Why did good news trigger a liquidation event? The answer lies in a ticking clock: the critical December 31st deadline for the trouble-plagued Vineyard Wind project. In this episode, we break down why investors are fleeing the offshore wind risk, whether the mark...

Affirm just pulled off the market’s wildest reversal of the month. What started as a 6% pre-market drop on news of a massive $750 million debt offering turned into a 12% surge by the closing bell. Why? Because Wall Street realized this wasn't a desperate cash grab—it was a calculated power move. In this episode, we break down how Affirm is using cheap debt to fund a $300 million stock buyback, for...

Applied Digital just erased nearly 20% of its value in a brutal two-day selloff—despite having zero bad news of its own. The culprit? "Sector guilt." After Fermi Inc’s crash and soft signals from Oracle, investors are panic-selling the AI infrastructure trade. In this episode, we break down whether this is a reckless "baby out with the bathwater" moment given APLD's massive CoreWeave contract, or...

Fermi Inc just suffered a catastrophic 34% crash, closing at $10 just two months after its hot IPO. The catalyst? The mysterious "Anchor Tenant" behind its massive Project Matador suddenly walked away, terminating a vital $150 million funding deal. In this episode, we break down why the "trust me" phase is officially over, whether the company is now just a land developer with no customers, or if t...

Robinhood just hit a massive speed bump, crashing 9% after an incredible 270% rally in 2025. Investors panicked over a sharp drop in trading volumes—equity down 37%—and a decline in funded customers. But is the retail army actually retreating, or is this just a "hangover" after a record-breaking October? We break down the technical reality behind the user drop, the valuation risks, and whether thi...

Pan American Silver just ripped 11% higher in a single session, capitalizing on silver smashing through an all-time high of $60 per ounce. Despite a slight earnings miss, Wall Street is all-in on the miner’s record free cash flow and the massive payoff from its Yamana Gold acquisition. In this episode, we break down why the "poor man's gold" has suddenly become the rich man's trade, and whether bu...

Unilever just finalized its "Great Ice Cream Divorce," but the new standalone company (Ticker: MAG) stumbled right out of the gate, opening below its €12.80 reference price. The market gave the Ben & Jerry’s owner a chilly reception, valuing the spin-off at a lackluster €10 billion as index funds rush to sell. In this episode, we break down the mechanics of the 8-for-9 share consolidation, why...

Pure Storage just erased a quarter of its value overnight, crashing 25% despite beating revenue estimates and hitting earnings targets. Why the panic? The market just snapped out of its "AI trance." Investors realized they were paying software premiums (50x earnings) for hardware margins, creating a massive valuation disconnect compared to rivals like Dell. In this episode, we break down why Wall...

Zscaler just delivered a CEO’s dream: a classic "beat and raise" report with 26% revenue growth and increased annual guidance. The market’s reaction? A brutal 13% selloff. In this episode of Implied, we dissect the "high expectations hangover" that turned a stellar report into a bloodbath. With the stock trading at 16x sales but printing cash with unheard-of 52% margins, is this a harsh valuation...

Burlington Stores just got hammered, dropping nearly 12% despite crushing profit estimates and raising full-year guidance. The culprit? A meager 1% sales growth and an old nemesis: unseasonably warm weather. While competitors like TJX and Ross are hitting highs, investors are punishing Burlington for relying too heavily on coat season. In this episode, we break down why this "good news" became a d...

Novo Nordisk just hit a brick wall, dropping nearly 10% after its highly anticipated Alzheimer’s trial failed to deliver results. The stock has now lost half its value this year, a brutal reversal just days after rival Eli Lilly crossed the historic $1 trillion mark. Is the weight-loss king dead, or is this a massive market overreaction? In this episode, we break down the failed "Evoke" data, the...

Billion To One (BLLN) just delivered a massive 15% daily surge, effectively doubling its stock price just weeks after its IPO. Why is Wall Street obsessing over this new biotech player? It comes down to "Molecular Counting"—proprietary tech claiming to be 1,000x more sensitive than standard PCR—and a massive $500 million cash war chest.

Affirm stock just shed 14% in a single week, leaving investors baffled. The twist? The company actually crushed earnings, posting 34% revenue growth and a surprise profit. The problem isn't Affirm—it’s Klarna. Wall Street is terrified that Klarna’s reliance on "junk fees" will trigger a regulatory crackdown that drags the whole sector down.

Chipotle’s stock has been cut in half, crashing 50% over the last 12 months as the "growth at any cost" era comes to a screeching halt. Why the massive freefall? Beyond the brutal 0.3% same-store sales growth, a new class-action lawsuit regarding "inconsistent portion sizes" has rattled investors, confirming that fixing the viral complaints is destroying margins.